Skip to content

Fragment-based diffusion modeling and molecular dynamics simulation validation for the discovery of PD-L1 small-molecule inhibitors.

Jul 2026 · Molecular diversity · 0 citations · 65 references
Medicine

TL;DR

Fragment-based diffusion modeling is an efficient and interpretable strategy for the discovery of computationally prioritized PD-L1 small-molecule candidate inhibitors and offers a promising framework for tackling challenging targets in cancer immunotherapy.

View source

Similar papers

Open access Aug 2026

Peptide-Functionalized Gold Nanoparticles Targeting PD-L1: Design via a Molecular Dynamic Driven Approach and Further Experimental Validation.

Design and development of theranostic gold nanostructures functionalized with PD-L1-targeting peptides (PTP, sPTP, and rPTP) whose sequences were identified combining structural analysis of the PD-1/PD-L1 interaction interface and molecular dynamics simulations are reported.

Micaela Giannetti, Marina Gobbo, Lucio Litti et al. · 0 citations
Open access Aug 2026

Building TIPE2 Inhibitors from Quadrant System for Fragment-Based Docking

It is demonstrated that quadrant-based fragment docking provides an effective strategy for designing inhibitors targeting proteins with large binding cavities and provides promising lead compounds for the development of TIPE2 inhibitors.

Dorothea West, Pearl Miller, Jerica Wilson et al. · 0 citations
Review Open access Jul 2026

One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules

A comparative, structure-driven analysis of PD-L1 complexes deposited in the Protein Data Bank is presented and it is demonstrated that distinct inhibitory modalities converge on the same functional CC′FG hotspot region while employing fundamentally different neutralization mechanisms.

Imma Capriello, T. Moreira Pereira, Gustavo Barbosa Reis et al. · 0 citations
Jul 2026

Abstract P69: Covalent Inhibition of CLIC1: A Novel Strategy for Anti-Cancer Drug Discovery

The crystal structure of the CLIC1-covalent inhibitor complex at 1.9 Å resolution is solved, providing invaluable insights into their binding mechanisms and paving the way for further anti-cancer drug discovery.

Sibasis Sahoo, L. Panchariya, Uma Chaudhary et al. · 0 citations